Trial Profile
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BV-ALLO
- 26 Nov 2020 Status changed from not yet recruiting to recruiting.
- 02 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Aug 2023.
- 02 Jul 2019 Planned primary completion date changed from 1 Dec 2021 to 1 Aug 2022.